Dr. Ramzi Abboud attended medical school at the University of Rochester where he graduated Alpha Omega Alpha in 2014. He then matriculated to Washington University School of Medicine in St. Louis completing his residency in Medicine in 2017 and a fellowship in Hematology/Oncology in 2020. Dr. Abboud then joined the faculty as an Instructor on the Clinician Track as of July 1, 2020 in the Division of Oncology. He participated in the American Society of Hematology Clinical Research and Training Institute and the Washington University Clinical Scientist Training and Research Program. His awards include the Knowlton Incentive for Excellence Award and the American Society of Hematology Research Training Award for Fellows. He currently serves as a laboratory based investigator and a primary investigator for investigator initiated clinical trials.
Dr. Abboud’s research is focused on acute leukemia, stem cell transplant and cellular therapies. He has an interest in immune based therapies and novel associated toxicities such as the cytokine release syndrome (CRS). His clinical research focuses on haploidentical transplantation and reducing graft versus host disease (GVHD) and CRS in this transplant platform. His work includes modeling and inhibition of the Janus Kinase/Signal Transducer and Activator of Transcription pathway in order to make cellular therapies safer and more effective. His laboratory research focuses on invariant natural killer T-Cells, a T-cell subset that bridges innate and adaptive immune responses, as a novel platform for cellular therapies. In addition, he is studying other platforms to boost the effects and safety profile of traditional autologous chimeric antigen receptor T-cell therapies.